Diligence memo · auto-generated · as of July 2, 2026
General Proximity
General Proximity: limited disclosed financing to assess.
Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.
Businessfiled
General Proximity operates in Biotech, based in San Francisco, CA, USA. The next generation of induced-proximity medicines.
Sub-sector tags: Biotech, Drug discovery.
Capital & rounds (filed)filed
General Proximity has raised — in disclosed capital across 0 recorded rounds, aggregated from public filings.
Valuation (modeled)modeled
No modeled valuation — too little disclosed financing to estimate one.
Financing rhythm & timingmixed
Not enough dated financing history to read a financing rhythm.
Comparablesmixed
Capital scale ranks ahead of 67% of Biotech peers (233 compared).
Modeled value ranks above 67% of those peers.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.